Archive | Uncategorized RSS for this section

In memory of Dr. Melvin Freedman

Dr. Melvin (Mel) Freedman, former Head of the Division of Haematology/Oncology at SickKids, passed away on January 2. He leaves a rich legacy from which his colleagues in Haematology/Oncology continue to benefit. Below, a tribute from the team:

Dr. Melvin Freedman, an iconic international leader in the field of paediatric haematology/oncology since the late 1960s, passed away in his sleep on January 2, 2019 after a long and courageous battle with cancer.

Mel was born and raised in New Brunswick, completed his medical training at McGill University, and his paediatric and haematology residencies in the United States before being recruited to SickKids in 1971, where he spent his entire professional career. Over the years, many institutions from around the world attempted to recruit Mel, but he was passionate about SickKids and never saw the need to move elsewhere.

Mel’s career spanned a remarkable revolution in childhood cancer care. He witnessed the initial uses of chemotherapy to treat a variety of childhood cancers and cared for many of the first children with leukemia who were actually long-term survivors of their disease. Toward the close of his career, he saw the emergence of molecular and genomic technologies being applied to the practice of paediatric oncology and haematology.

In addition to being a compassionate, caring and dedicated doctor to his young patients and their parents, Mel was a brilliant, productive scientist whose work expanded our understanding of haematopoiesis, leukemia stem cell biology, development of rational approaches to leukemia clinical trial design and innovative management of haemoglobinopathies, including allogeneic stem cell transplantation. Mel also pioneered research and treatment of congenital neutropenia and other inherited bone marrow failure syndromes.

Mel’s legacy is measured not only in the thousands of children who benefited from his care and research, but also the innumerable students, residents, junior faculty, nurses and all allied health-care colleagues who he mentored with wisdom, kindness and patience – who went on to build their own careers around the world. Mel was an inspiring teacher, who showed his students the value of asking cutting questions and had the gift of real wit that could level any pretense.

Among the many accolades recognizing his many contributions, one that resonates particularly is the Medical Staff Association Citizenship Award in 2012 — a testament to a truly renaissance man who selflessly gave so much to his colleagues, his patients and our institution.

He was a greatly admired leader both here and at the University of Toronto in many capacities, including Head of the Division of Hematology/Oncology in the 1990s, Chair of the SickKids Research Ethics Board and Head of the Department of Pediatrics Academic Promotions Committee. In each of these roles, he was respected at all levels of governance and admired by all who came to know him. Even since his retirement and during his illness, Mel continued to enjoy hearing stories about and taking great pride in the successes of his colleagues and friends.

Mel leaves behind his wife Lila, his children Monica and Jamie, and many grandchildren. His passing leaves a great hole in the hearts of all who knew him in their academic or personal lives. At the same time, we know that our lives are much the richer for having had the honour to have been in his company.

Advertisements

REGISTRATION NOW OPEN for the C17 Next Generation of Early Phase Trials: Moving the Bar in Pediatric Oncology workshop (04-Nov- 2017, pre-session meeting at CCRA conference in Vancouver)

 

C17 “Next Generation of Early Phase Trials: Moving the Bar in Pediatric Oncology” educational workshop will be held on Saturday, 4 November 2017 in Vancouver, BC. The workshop is in response to the C17 DVL needs assessment that was completed last year; members from all C17 DVL sites and PROFYLE clinical site leads are encouraged to attend.

The workshop is a full day, pre-session workshop at the CCRA Canadian Cancer Research Conference. We hope that most attendees at our workshop will take the opportunity to attend the full conference as well.

The workshop will be designed to educate investigators on traditional models of early phase trials as well as newer approaches to drug development. We will also cover regulatory, ethical, advocacy and access aspects of early phase trials. The workshop will proved education, discussions, panels and time for questions.

Travel and accommodation booking information will be emailed to you upon completion of the registration.

 

 

CAN YOU RECOGNIZE THE SYMPTOMS OF THE DICER1 SYNDROME? New DICER1 online resource physicians and patients, including variant maps, biobanking instructions and genetic testing. www.dicer1syndrome.ca

With over 50 years of combined research experience, clinician-researchers Dr. William Foulkes and Dr. David Malkin, are pleased to introduce a new resource for patients and healthcare professionals interested in learning more about DICER1 syndrome. Until now, our research has contributed to allowing caregivers recognize the major features of the syndrome, counsel families about the mutation status in their families, and offer surveillance for certain conditions that can occur in those carrying DICER1 mutations. However, due to the rarity of DICER1 syndrome and related tumors, the study of DICER1 syndrome has been limited by the number of cases which occur. This Canadian research network will work to provide an international resource for the dissemination of the information that has been learned about DICER1 syndrome (available in English, French, and Spanish), a DICER1 sample database available for researchers at no cost, and a tool for broadening our reach for case and specimen collection. Please visit our website (www.dicer1syndrome.ca) or contact Evan Weber (evan.weber2@mail.mcgill.ca) for more information.

NAIT: KTE-C19 CAR T cell study open + May newsletter available

KTE-C19 now open: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia.  For more information see:  https://clinicaltrials.gov/ct2/show/NCT02625480

 

The May 2017 NAIT newsletter can be found HERE.  For more information on current and upcoming trials, please visit www.sickkids.ca/centres/gfcc/nait/index.html or send an email directly to nait.info@sickkids.ca

Solid Tumours: Dr. Daniel Morgenstern
Leukemia/Lymphoma: Dr. Jim Whitlock
CNS: Dr. Eric Bouffet
Patient Navigator: Karen Fung

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html

HELPING FAMILIES NAVIGATE:  To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health.

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

CCSRI – change of deadline dates for upcoming competitions

CCSRI announced their upcoming competition deadlines, and included the note that some dates have changed. Details will be made available shortly for the following:
  • Knowledge to Action grants (abstract registration deadline April 1; funding start November 1, 2017)
  • Impact grants (letter of intent deadline April 3; funding start February 1, 2018)
  • Innovation grants with a focus only on prevention  (abstract registration deadline May 1; funding start November 1, 2017)
  • Quality of Life grants (letter of intent deadline May 15; funding start February 1, 2018)

Visit the CCSRI website for information: www.cancer.ca/research

 

The next BioCanRx LOI deadline is March 1

https://biocanrx.com/research/research-program/research-funding/our-funding-opportunities

BioCanRx invites researchers and their teams to participate in its open, rolling research funding call. The open call builds on past and ongoing investments in the area of cancer biotherapeutics and aims to strengthen Canada’s ability to develop this emerging and promising area of cancer research.

February NAIT newsletter available

The February 2017 NAIT newsletter can be found HERE.

For more information on current and upcoming trials, please visit

www.sickkids.ca/centres/gfcc/nait/index.html

or send an email directly to nait.info@sickkids.ca

Solid Tumour: Dr. Daniel Morgenstern
Leukemia/Lymphoma: Dr. Jim Whitlock
CNS: Dr. Eric Bouffet
Patient Navigator: Karen Fung

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html

HELPING FAMILIES NAVIGATE:  To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health.

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and SickKids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

JOB POSTING: Nurse Practitioner – Haematology Oncology Inpatient Unit (8A) at Sick Kids

“Nurse Practitioners at SickKids are expert scholarly practitioners who advance nursing practice and provide the very best standards of care to children and families. They work in a collaborative environment with many other providers across all health disciplines. They are leaders and advocates, pushing the boundary of practice with innovative models of care and initiatives that improve the care and the lives of children and families.”

We are currently looking for a Nurse Practitioner to join the Division of Haematology Oncology,  Inpatient Unit (8A) and Outpatient programs to provide leadership and promote excellence in family-centred nursing care through the five main role components of expert practice, education, consultation, research and leader/change agent.

Here’s What You’ll Get To Do

  • Integrate nursing and medical skills and knowledge within a broad scope of advanced nursing practice
  • Assume a leadership role in influencing clinical nursing practice and the provision of care
  • Provides comprehensive health care to specific patient populations
  • Is a member of the health care team, and serves as the key contact person for patient and families cared
  • Coordinate the interdisciplinary plan of care for select patient populations
  • Integrate research into practice
  • Create, utilize and/or disseminate new knowledge
  • Conduct environmental assessments (home, community, school) and help guide child/family through the treatment program
  • Identify and link to services and resources in community
    Provide assistance with acquiring specialized equipment for children in the program

Here’s What You’ll Need

  • Master’s of Nursing or equivalent with a clinical focus
  • Completion of a Post-Master of Nursing (NP Field) Diploma
  • Registration with the College of Nurses of Ontario, preferably within the RN (Extended Class)
  • 3 – 5 years of clinical nursing experience in paediatrics
  • Experience in Hematology/Oncology, chemotherapy administration and palliative care is an asset
  • Previous experience in a leadership role
  • Ability to act as a change agent, and foster teamwork and consensus
  • Innovative critical thinking with excellent communication, public speaking and problem solving skills
  • Knowledge of theoretical frameworks and research application

Employment Type

  • Full-Time, Temporary Employment (1 year + 1 day contract, 35 hours per week).
  • 8A and outpatient program rotation as needed.
  • This position offers health and dental coverage, vacation time, sick time, and personal days.

Full posting and application instructions: @font-face { font-family:

https://career.sickkids.ca/psp/CRPRD/CAREER/HRMS/c/HRS_HRAM.HRS_APP_SCHJOB.GBL?Page=HRS_APP_JBPST&Action=U&FOCUS=Applicant&SiteId=1&JobOpeningId=6785&PostingSeq=1

New Agents & Innovative Therapy Program November newsletter is available now

The November 2016 NAIT newsletter can be found HERE.

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at www.sickkids.ca/HaematologyOncology/nait/index.html

HELPING FAMILIES NAVIGATE:  To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health.

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and SickKids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

JOB POSTING: Pediatric Oncology Clinical Associate (Saskatchewan Cancer Agency, Permanent Position, apply by Nov 30)

The Saskatchewan Cancer Agency provides leadership to cancer care in Saskatchewan and operates prevention and early detection programs, conducts innovative research and runs a safe, patient and family-centred Pediatric Oncology Program from our two cancer centres – the Allan Blair Cancer Centre in Regina and the Saskatoon Cancer Centre.

We are seeking a permanent full-time Clinical Associate to work with our team.  This physician, while based in Regina at the Allan Blair Cancer Centre, will be part of a provincial team providing pediatric cancer care to the residents of Saskatchewan.

The physician will work as part of a multidisciplinary team and under the supervision of pediatric oncologists.  The physician will participate in daily rounds, provide care to pediatric oncology patients admitted at the Regina General Hospital and, as required, see patients in the Cancer Centre who require assessment and follow up care.

The ideal candidate will have certification in Pediatrics or an equivalent certification and experience. The candidate must hold certification with the Medical Council of Canada or at minimum have completed the Medical Council of Canada Evaluating Exam (MCCEE) and be eligible for licensure with the College of Physicians and Surgeons of Saskatchewan. In accordance with Canadian immigration requirements, preference will be given to Canadian citizens and permanent residents of Canada.

Saskatchewan is a growing and prosperous province. We have excellent education opportunities for young and old and we offer a rich cultural and recreational environment to suit families and independent living. Saskatchewan offers a world of endless possibilities. #ExploreYXE

The Saskatchewan Cancer Agency offers an attractive compensation, benefits and relocation assistance package. The annual salary is commensurate with the individual’s training and experience and within the range of $216,467-$319,309.   Interested applicants are invited to submit their curriculum vitae by November 30, 2016 to:

Carolyn Petersen, Physician Recruitment & Retention Consultant
Saskatchewan Cancer Agency
120-1804 McOrmond Drive
Saskatoon, Saskatchewan Canada S7S 0A6
Facsimile:  (306) 655-0935
E-mail: carolyn.petersen@saskcancer.ca